Hereditary Angioedema Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Collaboration and Other Developments
The pipeline of hereditary angioedema is increasing on account of rising instances of angioedema, globally. Currently, an estimated prevalence of hereditary angioedema in the world is 1 in 10,000 to 1 in 150,000. Major factors driving the growth of pipeline for hereditary angioedema include increasing prevalence of attacks of angioedema and rising cases of angioedema in association with other conditions like significant hypotension resulting from abdominal attacks, low market penetration as very less number of companies are making an analog and increasing awareness of health issues. The impairment in quality of life and rising medical cost also act as the driving factor for the hereditary angioedema pipeline.
Explore Report at: https://www.psmarketresearch.com/market-analysis/hereditary-angioedema-therapeutics-pipeline-analysis
Angioedema can be defined as swelling of mucosal or skin tissues, which leads to extravasation of fluid into the interstitium and loss of vascular integrity. There are two basic types of angioedema, histaminergic angioedema and non-histaminergic angioedema. Histaminergic is basically associated with urticaria. Non-histaminergic angioedema is usually not associated with urticaria, and is only mediated by bradykinin. The non-histaminergic angioedema is further divided in four categories namely, angiotensin-converting enzyme (ACE) inhibitor-associated angioedema, hereditary angioedema (HAE), idiopathic angioedema and acquired angioedema. Hereditary angioedema is symptomatized as episodic swelling disorder and arises from autosomal dominant trait. Clinical features include nonpitting edema of external body surfaces, abdominal pain, swelling of the extremities and swelling of the mouth and throat, which can lead to asphyxiation.
Request for table of Content at: https://www.psmarketresearch.com/market-analysis/hereditary-angioedema-therapeutics-pipeline-analysis/toc-sample
Some of the companies having a pipeline of hereditary angioedema therapeutics include BioCryst Pharmaceuticals, Inc., CSL Limited, Dyax Corp., Cevec Pharmaceuticals GmbH, Global Blood Therapeutics, Inc., Isis Pharmaceuticals, Inc., iBio, Inc. Pharming Group N.V., Ra Pharmaceuticals, Inc., Shire Plc.
Ulcerative Colitis Therapeutics Pipeline Analysis 2017 — Clinical Trials & Results, and Other Developments
The ulcerative colitis pipeline analysis report covers approximately 89 drug candidates, of which 68 drug candidates are in active stage. Among the active drug candidates, one drug is in NDA filed stage, 11 are in Phase III stage, 28 are in Phase II stage, 13 are in Phase I stage, 14 are in Pre-Clinical stage and one drug is in Discovery stage of development. The development of 18 ulcerative colitis drug candidates is found to be inactive and three drug candidates are discontinued.
Ulcerative colitis is a chronic inflammatory disease, which basically affect colonic mucosa. The main identified symptoms of the disease are bloody diarrhea, abdominal cramps and fatigue. Some of the other symptoms include, fever, vomiting, anorexia, abdominal distension and bloating. The treatment approaches to this disease mostly include the use of small molecules and monoclonal antibodies, which are being developed to target and reduce the inflammatory mediators. The treatment of ulcerative colitis includes tumor necrosis factor inhibitors, such as adalimumab, golimumab and infliximab.
Browse Detailed Report Description at: https://www.psmarketresearch.com/market-analysis/ulcerative-colitis-pipeline-analysis
Pipeline Insights
The pipeline for ulcerative colitis was analyzed based on route of administration, molecule type and phase of drugs. Based on route of administration, around 46.0% of the active pipeline drug candidates of ulcerative colitis are being developed to be administered by oral route and 29.0% by are being developed to be administered by intravenous and subcutaneous route. Approximately 3.0% drug candidate are being administered by parenteral route, and 4.0% drug candidates are administered by intravenous; subcutaneous route. The route of administration of 29.0% drug candidates is undisclosed. The route of administration of 18.0% drug candidates are being administered by intravenous infusion, rectal, topical and others.
Several pharmaceutical companies engaged in the development of the ulcerative colitis drug candidates include, but are not limited to, Novartis Pharmaceuticals, EA Pharma Co., Ltd., Celgene Corporation, Galapagos NV, Lipid Therapeutics GmbH, and Momenta Pharmaceuticals, Inc.
Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/ulcerative-colitis-pipeline-analysis/report-sample
Some of the key players developing ulcerative colitis therapeutics include EA Pharma Co., Ltd., Celgene Corporation, InDex Pharmaceuticals AB, F. Hoffman-La Roche AG, Sigmoid Pharma Ltd., Pfizer, Inc., Momenta Pharmaceuticals, Inc., Johnson & Johnson, Arena Pharmaceuticals, Inc., and Novartis AG.
Hodgkin’s Lymphoma Therapeutics Pipeline Analysis 2017 - Collaboration and Other Developments
The Hodgkin’s lymphoma therapeutics pipeline is expected to witness considerable growth in the coming years as the researchers are making novel drug delivery system for the treatment for cancer. The government agencies such as National Cancer Institute and American Cancer Society are supporting the growth of the Hodgkin’s lymphoma (HL) therapeutics pipeline by providing funding, designations and grants for speeding up the drug development process. High prevalence of cancer, increasing awareness regarding cancer treatment, technological advancements and high demand for safe and effective medication are driving the growth of the Hodgkin’s Lymphoma therapeutics pipeline.
Explore Report at: https://www.psmarketresearch.com/market-analysis/hodgkins-lymphoma-therapeutics-pipeline-analysis
Hodgkin lymphoma (HL) or Hodgkin’s disease is an uncommon cancer of the lymphatic system, such as lymph nodes. The lymphatic system is made up of a network of vessels and glands that spread throughout the body. The vessels of lymphatic system known as lymphocytes carrying clear fluid known as lymph, contains lymphocytes (white blood cells that help combat infection). The lymphatic is a part of the human body’s immune system. In Hodgkin’s lymphoma, the patient experiences a painless swelling in a lymph node, usually in the neck, armpit or groin.
Ono Pharmaceuticals and Bristol-Myers Squibb are in the process of developing Opdivo for the treatment of Hodgkin’s disease. Seattle Genetics has developed ADCETRIS (brentuximab vedotin) as an antibody drug conjugate for Hodgkin’s disease. Merck & Co., Inc. has also developed Keytruda for the treatment of Hodgkin’s lymphoma. Though, major companies are developing promising drugs for Hodgkin’s lymphoma treatment, the new entrants are facing the challenge of fulfilling the relapsed or refractory (R/R) Hodgkin’s lymphoma patients’ unmet needs, and of bringing a reduction in the adverse effects of current treatments in the long term, thereby improving patients’ overall survival.
Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/hodgkins-lymphoma-therapeutics-pipeline-analysis/toc-sample
Some of the companies having a pipeline of Hodgkin’s lymphoma therapeutics include Bristol-Myers Squibb Co., Merck & Co. Inc., Pfizer, Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Affimed Therapeutics AG, Aeterna Zentaris Inc., Incyte Corporation, and 4SC AG.
Testicular Cancer Therapeutics Market Development, Growth and Demand Forecast to 2023
Global testicular cancer therapeutics market is growing with the increasing prevalence of testicular cancer. The market is expected to witness moderate growth, since there are already more than 15 drugs that exist in the market for the treatment of testicular cancer. Increasing prevalence of cancer and rising demand for the medications with better efficacy and less side effects can be attributed as an opportunity for oncology. The regulatory bodies such as USFDA, EMA are supporting the growth of the global market by providing increased funding, designations and grants for speeding up the drug development process.
Explore Report at: https://www.psmarketresearch.com/market-analysis/testicular-cancer-therapeutics-market
Testicular cancer is the tumor that develops in the testicles. Testicles are the glands found in men that produce testosterone hormone and sperms. The cause of testicular cancer is attributable to enormous growth of testicular cells due to some abnormalities, resulting in the formation of tumor in testicles, causing testicular cancer. Cryptorchidism, inguinal hernia, congenital abnormalities, abnormal testicular development and family history can increase the risk of testicular cancer. Mumps orchitis are also one of risk factors which is a very rare complication of mumps, which involves the inflammation of testicles. Pain, swelling, discomfort, sensation of heaviness and sudden fluid accumulation in scrotum are the main symptoms of testicular cancer.
Diagnosis of testicular cancer is done through a blood test, ultrasound and biopsy. Also, the type of testicular cancer is determined with the diagnosis along with its stage. There are two types of testicular cancer- seminoma testicular cancer and non- seminoma testicular cancer. After the diagnosis, the treatment options are selected according to the stage and the type of testicular cancer. The treatment options that are available to the patients are chemotherapy, radiation therapy and surgery. Surgery include orchidectomy, removal of both the testicles, lymph node surgery and hormone replacement therapy.
Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/testicular-cancer-therapeutics-market/toc-sample
Some of the key players operating in the global testicular cancer therapeutics market are Ovation Pharmaceuticals, Inc., ZIOPHARM Oncology Inc., Bristol-Myers Squibb Company, Hospira Inc., Teva Pharmaceutical Industries Ltd., Fresenius Kabi AG and Teva Parenteral Medicines, Inc.
Vascular Imaging Systems Market Size, Development and Demand Forecast to 2023
According to the study, the global vascular imaging systems market is likely to grow significantly, during the forecast period, due to increasing healthcare expenditure, increasing prevalence of cancer and cardiovascular diseases and rising awareness about imaging techniques due to various conferences and seminars. In addition, growing geriatric population and launch of technologically advanced products contribute to the growth of the market. High cost, stringent regulatory requirements, shortage of helium for magnetic resonance imaging and increasing risk of cancer due to exposure to radiations are the key factors restraining the global market growth.
Browse Report Overview at: https://www.psmarketresearch.com/market-analysis/vascular-imaging-systems-market
Insights on market segments
As per the findings of research, based on product, the CT imaging system is the most preferred vascular imaging system, globally. Based on application, cardiology holds the maximum share of the global market. Hospitals have been the largest end users of the global vascular imaging systems market.
Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/vascular-imaging-systems-market/report-sample
North America stands as the largest vascular imaging systems market
Geographically, North America has been the largest market for vascular imaging systems, where the U.S. has been the largest contributor to the regional market. Increasing awareness about imaging techniques has been driving the growth of the North American market. In Europe, Germany has been the largest contributor to the market, followed by the U.K. and France. Asia-Pacific market is expected to grow at the highest CAGR, during 2017 - 2023, owing to increasing prevalence of cancer and cardiovascular diseases.
Key players in the vascular imaging systems market
Some of the key players in the global market include Siemens AG, General Electric Company, Hitachi Ltd., and Koninklijke Philips N.V., Carestream Health, Inc., Hologic, Inc., Esaote S.P.A, Shimazdu Corporation, Canon Inc., Orthoscan, Inc., and Fujifilm Corporation.
Breast Imaging Technologies Market Development, Growth and Forecast to 2020
The global breast imaging technologies market is growing significantly due to technological advancement in the detection of breast cancer in the industry. Massive unexplored market in breast imaging technologies industry of developing economies are creating ample opportunities for the breast imaging technologies market to grow at a considerable rate in the coming years.
Explore more about Breast Imaging Technologies Market: https://www.psmarketresearch.com/market-analysis/breast-imaging-technologies-market
The advanced research and development facilities and new product developments by the companies are supporting to address the demand for the breast imaging technologies industry. However, strict regulatory approval procedures, and unfavorable reimbursement policies in the developing countries are posing a challenge for the growth of the breast imaging technologies market.
Breast cancer is the most common cancer in women. According to International Agency for Research on Cancer (IARC) and World Health Organization (WHO), globally, approximately 1.7 million new cases of breast cancer were diagnosed in 2012. As the incidence of breast cancer is increasing significantly, development of improved technology with less radiation exposure is also expected to support the growth of the breast imaging technologies market.
Request for Table of Content: https://www.psmarketresearch.com/market-analysis/Breast-Imaging-Technologies-Market/toc-sample
Geographically, North America will be leading the global breast imaging technologies market in the coming years due to technological advancement in breast imaging, rising awareness of early detection of breast cancer and increasing government initiatives and funding in research and product innovations in the region. Moreover, Asia-Pacific is the fastest growing region in the global breast imaging technologies market. The major reasons for the fastest growth in the region are increasing healthcare expenditure, increasing incidence and prevalence of breast cancer cases, increasing government initiatives and investment in breast imaging technologies, and improving healthcare infrastructure in the region. Moreover, the breast imaging technologies market is growing due to increasing awareness about women health in the emerging countries, such as India and China, of Asia-Pacific region.
Browse Other Related Report at: https://www.psmarketresearch.com/industry-report/medical-devices
Some of the companies operating in the breast imaging technologies market are Toshiba Corporation, Aurora Imaging Technologies, Dilon Technologies, Inc., Gamma Medica, Inc., Sonocine, Inc., Siemens Healthcare, Philips Healthcare, GE Healthcare, Dune Medical Devices, U-Systems, Inc., and Hologic, Inc.
Estrogen Receptor-Positive Breast Cancer Pipeline Analysis, 2017
The study analyzed that the estrogen receptor positive breast cancer pipeline comprises approximately 74 drug candidates, of which nine products are in Phase III, 16 products in Phase II, 18 products in Phase I, and three products are in Pre-Clinical stage. The development of 14 ER+ breast cancer drug candidates was found to be inactive, and 14 products were discontinued. ER+ breast cancer is the most common type of breast cancer diagnosed and refers to the cancer cells that have receptors on their surface to bind with estrogen. Breast cancer is a syndrome that affects the breast tissues. In breast cancer, cells in the breast grow in an uncontrollable manner and form tumor, which can be felt as a lump or can be viewed under x-ray. Invasion of new therapeutic agents, such as gene therapy, cell therapy and monoclonal antibodies are expected to provide an effective and concrete treatment for the disease, more in the light of the new technologies available.
Access Report Overview: https://www.psmarketresearch.com/market-analysis/estrogen-receptor-positive-breast-cancer-pipeline-analysis
Insights on pipeline analysis
As per the findings of the research, a major share of ER+ breast cancer pipeline drug candidates are being developed to be administered by oral route and rest by intravenous route and subcutaneous route. Most of the therapeutic candidates are being developed to be administered by oral route due to high patient compliance.
Several companies are developing ER+ breast cancer drug candidates in different phases. Novartis AG, Syndax Pharmaceuticals, Tesaro, Inc. and others have their ER+ breast cancer drug candidates in Phase III stage of development. Novartis AG has three drug candidates in Phase III stage and two drug candidates in Phase I clinical stage.
Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/estrogen-receptor-positive-breast-cancer-pipeline-analysis/report-sample
Some of the key players developing drugs for Estrogen Receptor-Positive (ER+) breast cancer are Chipscreen Biosciences, Ltd., Eli Lilly & Company, Genentech, Inc., Novartis AG, Ipsen, Syndax Pharmaceuticals, Inc., Tesaro, Inc Astellas Pharma Inc., AstraZeneca plc, and Bayer AG.
